OneSource Specialty Pharma, an associate of Strides Pharma, secured Rs. 801 crore from investors including HBM Healthcare Investments and WhiteOak Capital. With these funds, OneSource will reduce debt and enhance its manufacturing capabilities. The company aims to list its shares by March 2025 and targets being debt-free by FY26. Strides shareholders will benefit significantly from this transaction.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.